Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

12,957 total articles

Norwegian Cruise Line Holdings Enters into Employment and Equity Award Agreements with President and CEO

Norwegian Cruise Line Holdings Enters into Employment and Equity Award Agreements with President and CEO

Norwegian Cruise Line Holdings Ltd. announced the appointment of John W. Chidsey as President and CEO, effective February 2026, accompanied by a new employment agreement and a $48 million restricted share unit award designed to incentivize long-term shareholder value creation over four years. The equity award includes performance-based and time-ves…

Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders

Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders

Clearmind Medicine Inc., a Nasdaq-listed clinical-stage biotech company, announced the filing of a patent application in India for next-generation psychedelic compounds aimed at treating mental health disorders and addiction. This move expands the company's global intellectual property portfolio and builds on its licensing agreement with Yissum Res…

Streamex Corp. Clarifies and Refutes Inaccurate Claims Regarding Lock-Up Agreements; Co-Founders Morgan Lekstrom & Henry McPhie Enter into Voluntary 1 Year Lock-Up Agreements

Streamex Corp. Clarifies and Refutes Inaccurate Claims Regarding Lock-Up Agreements; Co-Founders Morgan Lekstrom & Henry McPhie Enter into Voluntary 1 Year Lock-Up Agreements

Streamex Corp. clarifies and disproves misleading third-party reports about the expiration of lock-up agreements related to its January 2026 financing. The company confirms that the previous lock-ups of certain shares held by co-founders Henry McPhie and Morgan Lekstrom were shorter than reported and that newly agreed voluntary one-year lock-ups ha…

Sportradar Files Its Annual Report on Form 20-F

Sportradar Files Its Annual Report on Form 20-F

Sportradar Group AG, a leading global sports technology company, announced the filing of its annual report on Form 20-F for the fiscal year ended December 31, 2025, with the SEC. The report is available to investors via the company’s website and SEC filings. Sportradar provides technology and services to sports federations, media, and betting opera…

SFL - Notice of Annual General Meeting 2026

SFL - Notice of Annual General Meeting 2026

SFL Corporation Ltd., a maritime shipping company listed on the NYSE, announced its Annual General Meeting to be held on May 11, 2026, with voting record date set for April 1, 2026. The company highlighted its stable dividend record since 2004 and provided a cautionary statement about risks and uncertainties affecting its business including market …

Aurora Mobile Partners with Soochow Securities to Advance Digital Transformation and Develop Intelligent Financial Services Platform

Aurora Mobile Partners with Soochow Securities to Advance Digital Transformation and Develop Intelligent Financial Services Platform

Aurora Mobile has entered into a strategic partnership with Soochow Securities to integrate its intelligent push notification platform, JPush, into Soochow Securities' 'Dongwu Xiucai' mobile app. This collaboration aims to improve real-time, secure delivery of financial notifications and personalized client communication, advancing Soochow's digita…

Legence Reports Fourth Quarter and Year End 2025 Financial Results

Legence Reports Fourth Quarter and Year End 2025 Financial Results

Legence Corp. reported record quarterly revenues of $737.6 million for Q4 2025, a 34.6% increase year-over-year, driven mainly by organic growth. The company posted a 53% increase in quarterly Adjusted EBITDA and a 49% increase in total backlog and awarded contracts to $3.7 billion. Strategic acquisitions including Bowers and Metrix enhance its mar…

Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

Autolus Therapeutics reported fourth quarter and full year 2025 financial results highlighted by $74.3 million in net product revenue for their CAR T cell therapy AUCATZYL, approved for relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). The company has launched AUCATZYL in the UK following positive NICE evaluation and expects conti…

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates

Werewolf Therapeutics announced its Q4 and full-year 2025 financial results, highlighting a reduced net loss and operational expenses compared to 2024. The company revealed its decision to explore strategic alternatives, including potential sale, merger, or collaborations to maximize shareholder value. With $57.1 million in cash at year-end, they e…

Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update

Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update

Humacyte, Inc. announced its financial results for Q4 and full year 2025 with revenues of $0.5 million and $2.0 million respectively, driven by the commercial launch of Symvess in the US and strategic international expansion efforts. The company secured a $1.475 million purchase commitment from Saudi Arabia for clinical evaluation and is pursuing r…

Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer

Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer

Radiopharm Theranostics has dosed the first patient in its Phase 1 clinical trial of RAD 402, a monoclonal antibody radiolabeled with Terbium-161, targeting KLK3 for advanced prostate cancer. The trial aims to assess safety, tolerability, biodistribution, and preliminary efficacy, with data from initial dose levels expected by mid-2026. Preclinical…

BROAD ARROW PRESENTS RARE OPPORTUNITY TO ACQUIRE FERRARI MONZA SP2 AT CONCORSO D’ELEGANZA VILLA D’ESTE AUCTION

BROAD ARROW PRESENTS RARE OPPORTUNITY TO ACQUIRE FERRARI MONZA SP2 AT CONCORSO D’ELEGANZA VILLA D’ESTE AUCTION

Broad Arrow Auctions, a part of Hagerty, is presenting a rare low-mileage Ferrari Monza SP2 at the Concorso d’Eleganza Villa d’Este auction in May 2026. The Monza SP2 is a highly collectible Icona series Ferrari, noted for its performance and exclusivity, expected to attract significant international bidder interest. This event highlights Broad Arr…

PDMR Shareholdings

PDMR Shareholdings

Diversified Energy Company announced that its President and CFO, Bradley Gray, has transferred 15,000 shares of the company's common stock to his family members as a gift, reducing his shareholding to approximately 0.30% of the company's issued share capital. The transaction was executed outside a trading venue and involved no consideration. The co…

Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older

Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older

Pharming Group announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion recommending marketing authorization for Joenja® (leniolisib) to treat activated phosphoinositide 3-kinase delta syndrome (APDS) in patients 12 years and older. The final European Commission decision is ex…

Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Artelo Biosciences, a clinical-stage pharmaceutical company, has entered into definitive agreements for a private placement under Nasdaq rules to raise approximately $11 million by issuing 3.19 million common shares or pre-funded warrants along with warrants exercisable for up to 6.38 million shares. The financing proceeds will be used for working …

Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million

Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million

Zenas BioPharma announced the pricing of concurrent public offerings including $200 million aggregate principal amount of 2.50% convertible senior notes due 2032 and 5 million shares of common stock priced at $20.00 per share, aiming to raise approximately $287.5 million net proceeds. The funds will support the planned U.S. commercial launch of obe…

Moomoo and the New York Mets Enter Second Year of Strategic Partnership to Continue Enhancing the Fan Experience

Moomoo and the New York Mets Enter Second Year of Strategic Partnership to Continue Enhancing the Fan Experience

Moomoo, a global investment and trading platform and a subsidiary of the Nasdaq-listed FHL Holdings, is entering the second year of its partnership with the New York Mets. The collaboration aims to enhance the fan experience at Citi Field through suite experiences, interactive events, and community engagement throughout the 2026 MLB season. The par…

Cambridge Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing March 30, 2026

Cambridge Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing March 30, 2026

Cambridge Acquisition Corp., a U.S.-based SPAC listed on Nasdaq, announced that starting March 30, 2026, investors will be able to separately trade its Class A ordinary shares and warrants, which were previously bundled as units. The shares and warrants will trade under the tickers 'CAQ' and 'CAQUW' respectively, while unsplit units will continue u…